The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas

Medical Oncology

Volumn 23, Issue 1, 2006, Pages 113-119

  Andersson, S ^a   Hellstrom A C ^a   Ren, Zhi Ping ^b   Wilander, E ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical adenocarcinoma; HPV; p53 gene mutation

Indexed keywords

DNA; PROTEIN P53;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DNA SEQUENCE; EXON; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; LYMPH NODE METASTASIS; MISSENSE MUTATION; ONCOVIRINAE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; STATISTICAL ANALYSIS; TUMOR DIFFERENTIATION; UTERINE CERVIX CARCINOMA; VIRUS CARCINOGENESIS; VIRUS DETECTION; WART VIRUS;

ADENOCARCINOMA; ADULT; AGED; DNA, VIRAL; FEMALE; GENES, P53; HUMANS; MIDDLE AGED; MUTATION; PAPILLOMAVIRIDAE; UTERINE CERVICAL NEOPLASMS;

EID: 33646875512     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:23:1:113     Document Type: Article

References (32)

1. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75(4):536-545.
2. Sasieni P, Adams J. Changing rates of adenocarcinoma and adenosquamous carcinoma of the cervix in England. Lancet 2001;357(9267):1490-1493.
3. Bergstrom R, Sparen P, Adami HO. Trends in cancer of the cervix uteri in Sweden following cytological screening. Br J Cancer 1999;81(1):159-166.
4. Bosch FX, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87(11):796-802.
5. Bosch FX, Munoz N. The viral etiology of cervical cancer. Virus Res. 2002;89(2):183-190.
6. Munoz N, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-527.
7. Skyldberg BM, Murray E, Lambkin H, Kelehan P, Auer GU. Adenocarcinoma of the uterine cervix in Ireland and Sweden: human papillomavirus infection and biologic alterations. Mod. Pathol. 1999;12(7):675-682.
8. Tenti P, et al. Human papillomavirus types 16 and 18 infection in infiltrating adenocarcinoma of the cervix: PCR analysis of 138 cases and correlation with histologie type and grade. Am J Clin Pathol 1996;106(1):52-56.
9. Andersson S, Rylander E, Larsson B, Strand A, Silfversvard C, Wilander E. The role of human papillomavirus in cervical adenocarcinoma carcinogenesis. Eur J Cancer 2001; 37(2):246-250.
10. Andersson S, et al. Types of human papillomavirus revealed in cervical adenocarcinomas after DNA sequencing. Oncol. Rep. 2003;10(1):175-179.
11. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989;243(4893):934-937.
12. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248(4951):76-79.
13. Crook T, Wrede D, Vousden KH. p53 point mutation in HPV negative human cervical carcinoma cell lines. Oncogene 1991;6(5):873-875.
14. Milde-Langosch K, Albrecht K, Joram S, Schlechte H, Giessing M, Loning T. Presence and persistence of HPV infection and p53 mutation in cancer of the cervix uteri and the vulva. Int J Cancer 1995;63(5):639-645.
15. Park DJ, Wilczynski SP, Paquette RL, Miller CW, Koeffler HP. p53 mutations in HPV-negative cervical carcinoma. Oncogene 1994;9(1):205-210.
16. Tenti P, et al. Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix. Am J Pathol 1998;152(4):1057-1063.
17. Saiki RK, et al. Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. N Engl J Med 1988;319(9):537-541.
18. Zehbe I, et al. Nonradioisotopic detection and typing of human papillomaviruses by use of polymerase chain reaction and single-strand conformation polymorphism. Diagn. Mol. Pathol. 1996;5(3):206-213.
19. Zehbe I, Wilander E. Nonisotopic ELISA-based detection of human papillomavirus-amplified DNA. Mod Pathol 1997; 10(3):188-191.
20. Alemi M, Andersson S, Sallstrom J, Wilander E. Rapid test for identification of a human papillomavirus 16 E6 L83V variant. Diagn Mol Pathol 1999;8(2):97-100.
21. Lungu O, Wright TC, Jr, Silverstein S. Typing of human papillomaviruses by polymerase chain reaction amplification with Ll consensus primers and RFLP analysis. Mol Cell Probes 1992;6(2):145-152.
22. Hedrum A, Ponten F, Ren Z, Lundeberg J, Ponten J, Uhlen M. Sequence-based analysis of the human p53 gene based on microdissection of tumor biopsy samples. Biotechniques 1994;17(1):118-119, 122-124, 126-129.
23. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253(5015):49-53.
24. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9(4):138-141.
25. Walboomers JM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 1999;189(1):12-19.
26. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996;77(11):2275-2279.
27. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54(18):4855-4878.
28. Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ, Vousden KH. Clonal p53 mutation in primary cervical cancer: association with human-papillomavirus- negative tumours. Lancet 1992;339(8801):1070-1073.
29. Fujita M, Inoue M, Tanizawa O, Iwamoto S, Enomoto T. Alterations of the p53 gene in human primary cervical carcinoma with and without human papillomavirus infection. Cancer Res. 1992;52(19):5323-5328.
30. Kim JW, et al. Human papillomavirus infection and TP53 gene mutation in primary cervical carcinoma. Acta. Oncol. 1997;36(3):295-300.
31. Jiko K, Tsuda H, Sato S, Hirohashi S. Pathogenetic significance of p53 and c-Ki-ras gene mutations and human papillomavirus DNA integration in adenocarcinoma of the uterine cervix and uterine isthmus. Int J Cancer 1994; 59(5):601-606.
32. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102(5A):3-8.